Weida Tong Institution-verified

Sourced from institutional research profiles (UAMS TRI or ARA).

◆ ARA Academy

Division Director

NCTR

Last publication 2025 Last refreshed 2026-05-16

faculty

weida.tong@fda.hhs.gov

82 h-index 550 pubs 29,795 cited

Research Areas

Links

ORCID Lab Website Research Group

Edit your profile

OverviewAI-generated summary

Weida Tong leads a research group focused on regulatory science, with a particular emphasis on the application of bioinformatics and emerging technologies. Tong's work investigates the impact of new technologies on regulatory science and explores the use of AI-based language models in drug discovery and development. This research area intersects with public health and the evaluation of scientific reporting guidelines, such as the STORMS checklist for human microbiome research.

Further research interests include the regulatory landscape of nanotechnology and nanoplastics, and the analytical validation of sequencing assays for precision oncology. Tong has a scholarly record with an h-index of 4, encompassing 11 publications and 640 citations. Key collaborators at the National Center for Toxicological Research include Joshua Xu (14 shared publications), Leihong Wu (7 shared publications), William Slikker (4 shared publications), and Binsheng Gong (4 shared publications). Tong is also recognized as an ARA Academy member (ARA Fellow).

Metrics

h-index: 82
Publications: 550
Citations: 29,795

Selected Publications

AI-powered topic modeling: comparing LDA and BERTopic in analyzing opioid-related cardiovascular risks in women (2025)

28 citations DOI OpenAlex
Is ChatGPT Ready for Public Use in Organ-Specific Drug Toxicity Research? (2025)

2 citations DOI OpenAlex
Bridging organ transcriptomics for advancing multiple organ toxicity assessment with a generative AI approach (2024)

14 citations DOI OpenAlex
Physiological liver microtissue 384-well microplate system for preclinical hepatotoxicity assessment of therapeutic small molecule drugs (2024)

20 citations DOI OpenAlex
Progress in toxicogenomics to protect human health (2024)

45 citations DOI OpenAlex
Text summarization with ChatGPT for drug labeling documents (2024)

13 citations DOI OpenAlex
Generation of a drug-induced renal injury list to facilitate the development of new approach methodologies for nephrotoxicity (2024)

19 citations DOI OpenAlex
Evaluation of QSAR models for predicting mutagenicity: outcome of the Second Ames/QSAR international challenge project (2023)

19 citations DOI OpenAlex
Measurement and Mitigation of Bias in Artificial Intelligence: A Narrative Literature Review for Regulatory Science (2023)

26 citations DOI OpenAlex
Quartet DNA reference materials and datasets for comprehensively evaluating germline variant calling performance (2023)

29 citations DOI OpenAlex
PLM-ARG: antibiotic resistance gene identification using a pretrained protein language model (2023)

33 citations DOI OpenAlex
A generative adversarial network model alternative to animal studies for clinical pathology assessment (2023)

47 citations DOI OpenAlex
The Quartet Data Portal: integration of community-wide resources for multiomics quality control (2023)

22 citations DOI OpenAlex
Author Correction: Quartet RNA reference materials improve the quality of transcriptomic data through ratio-based profiling (2023)

13 citations DOI OpenAlex
DICTrank: The largest reference list of 1318 human drugs ranked by risk of drug-induced cardiotoxicity using FDA labeling (2023)

32 citations DOI OpenAlex

View all publications on OpenAlex →

ARA Academy 2016 ARA Fellow

Dr. Tong's work emphasizes developing bioinformatic tools and methodologies to support FDA research, regulatory science, and personalized medicine. His notable initiatives include the Microarray Quality Control (MAQC) consortium, the Liver Toxicity Knowledge Base (LTKB), in silico drug repositioning for rare disease treatment, and the ArrayTrack suite for pharmacogenomics review.

Policy Impact

Develops bioinformatic tools supporting FDA regulatory science and personalized medicine, anchoring critical federal research infrastructure in Arkansas.